Simplify Propel Opportunities ETF (SURI) Fund Overview

Simplify Propel Opportunities ETF Company Overview

Simplify Propel Opportunities ETF (SURI) is an actively managed, non-diversified fund concentrating its investments in the biotechnology, pharmaceuticals, healthcare technology, and life science industries. The fund utilizes an opportunistic multi-asset strategy, investing in common stock, preferred stock, convertible bonds, and other securities within these sectors, demonstrating a beta of 1.00 and no dividend yield.

What Is the Investment Thesis for SURI?

Simplify Propel Opportunities ETF (SURI) presents a focused investment opportunity within the biotechnology, pharmaceuticals, healthcare technology, and life science industries. The fund's active management strategy aims to outperform passive benchmarks by capitalizing on specific opportunities within these sectors. Key value drivers include the sub-adviser's ability to identify undervalued assets and emerging trends, as well as the fund's flexibility to invest across various security types. However, the fund's non-diversified nature introduces potential risks, as its performance is heavily reliant on the success of a concentrated portfolio. A beta of 1.00 suggests the fund's volatility is similar to the overall market. The absence of a dividend yield may deter income-seeking investors. The fund's success hinges on the continued growth and innovation within the healthcare and life sciences industries, as well as the sub-adviser's ability to execute its investment strategy effectively.

Based on FMP financials and quantitative analysis

SURI Key Highlights

Actively managed ETF providing exposure to the biotechnology, pharmaceuticals, healthcare technology, and life science industries.

• Non-diversified fund, concentrating investments in its target sectors.
• Employs an opportunistic multi-asset strategy, investing in common stock, preferred stock, convertible bonds, and other securities.
• Beta of 1.00, indicating market-average volatility.
• No dividend yield, potentially less attractive to income-focused investors.

What Are SURI's Key Strengths?

Active management strategy with experienced sub-adviser.

• Flexibility to invest across various security types.
• Focus on high-growth biotechnology, pharmaceuticals, healthcare technology, and life science industries.

What Are SURI's Weaknesses?

Non-diversified portfolio, increasing risk.

• Reliance on sub-adviser's expertise and ability to execute investment strategy.
• No dividend yield, potentially less attractive to income-seeking investors.

What Are the Key Risks for SURI?

Regulatory changes and patent expirations impacting pharmaceutical and biotechnology companies.

• Clinical trial failures and product recalls affecting healthcare companies.
• Economic downturns reducing healthcare spending and investment.
• The fund's non-diversified portfolio increases its vulnerability to market volatility and sector-specific risks.

What Are SURI's Competitive Advantages?

• Active Management Expertise: The fund's sub-adviser possesses specialized knowledge and experience in the healthcare and life sciences sectors, allowing them to identify and capitalize on investment opportunities that may be missed by passive investment strategies.
• Flexibility: The fund's ability to invest across various security types, including common stock, preferred stock, convertible bonds, and structured notes, provides it with greater flexibility to adapt to changing market conditions and pursue a wider range of investment opportunities.
• Concentrated Portfolio: The fund's non-diversified approach allows it to focus its investments on its highest-conviction ideas, potentially leading to higher returns compared to diversified ETFs.

What Does SURI Do?

Simplify Propel Opportunities ETF (SURI) is an actively managed exchange-traded fund (ETF) designed to provide investors with exposure to the biotechnology, pharmaceuticals, healthcare technology, and life science tools and services industries. Unlike passively managed ETFs that track a specific index, SURI employs an opportunistic multi-asset strategy, allowing its sub-adviser to actively select investments based on market conditions and perceived opportunities. The fund's investment universe includes common stock, preferred stock, convertible bonds, structured notes, corporate notes and bonds, and ETFs that primarily invest in the aforementioned security types. As a non-diversified fund, SURI concentrates its investments, allocating more than 25% of its net assets to securities within its target industries. This approach can potentially lead to higher returns but also exposes the fund to greater risk compared to diversified ETFs. The fund's active management style aims to capitalize on emerging trends and undervalued assets within the healthcare and life sciences sectors, seeking to generate alpha for its investors. However, the success of this strategy depends heavily on the sub-adviser's expertise and ability to navigate the complexities of these industries. The fund does not pay dividends.

What Products and Services Does SURI Offer?

• Invests in common stock of biotechnology companies.
• Allocates capital to pharmaceutical companies.
• Invests in healthcare technology companies.
• Invests in life science tools and services companies.
• Purchases preferred stock of companies in the healthcare sector.
• Invests in convertible bonds issued by healthcare companies.
• Acquires structured notes related to the healthcare industry.
• Invests in corporate notes and bonds of healthcare companies.

How Does SURI Make Money?

• The fund generates revenue through capital appreciation of its investments.
• The fund's sub-adviser actively manages the portfolio to identify and capitalize on investment opportunities.
• The fund charges a management fee to cover its operating expenses and compensate the sub-adviser.

What Industry Does SURI Operate In?

Simplify Propel Opportunities ETF (SURI) operates within the broader exchange-traded fund (ETF) industry, specifically targeting the biotechnology, pharmaceuticals, healthcare technology, and life science sectors. These sectors are characterized by high growth potential driven by innovation, aging populations, and increasing healthcare spending. However, they are also subject to regulatory scrutiny, patent expirations, and clinical trial risks. The competitive landscape includes both passive ETFs that track broad healthcare indices and actively managed funds with similar investment strategies. SURI differentiates itself through its concentrated, non-diversified approach and its sub-adviser's active management style.

Who Are SURI's Key Customers?

• Institutional investors seeking exposure to the healthcare and life sciences sectors.
• Financial advisors looking for actively managed ETF options for their clients.
• Retail investors interested in investing in the healthcare industry through an ETF.

SURI Financials

SURI Latest News

SURI Analyst Consensus

SURI MoonshotScore

What Investors Ask About Simplify Propel Opportunities ETF (SURI)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources